Top Gum Industries Ltd.

Top Gum Industries Ltd.

TTASE:TPGM
933.30
ILA
-7.20
(-0.77%)
-45.35EPS
162.75BMarket Cap
Top Gum Industries Ltd.
TASE:TPGM
(Tel Aviv Stock Exchange)

Recent

price

933.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
0.15
0.06
0.25
0.41
0.47
0.48
0.55
0.82
1.08
Revenue per Share
-0.01
- -
0.01
0.02
0.04
0.03
-0.06
-0.13
-0.15
Basic EPS, GAAP
-0.01
- -
- -
-0.08
-0.13
-0.27
-0.06
-0.08
-0.08
Free Cash Flow per Basic Share
- -
- -
0.01
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
0.15
0.5
0.49
0.63
0.58
0.74
1.03
Book Value per Share
- -
- -
0.15
0.5
0.48
0.62
0.56
0.63
0.75
Tangible Book Value per Share
94
94
94
81
94
96
108
123
117
Basic Weighted Avg Shares
14
6
24
33
44
46
59
101
127
Sales/Revenue/Turnover
-3.38
3.7
7.85
8.02
9.76
4.26
6.29
8.36
6.02
Operating Margin (%)
1
- -
2
2
2
2
2
6
10
Depreciation Expense
-1
- -
1
2
4
3
-6
-16
-18
Net Income, GAAP
- -
- -
22.13
12.36
15.71
19.07
- -
- -
- -
Effective Tax Rate (%)
-5.75
-0.89
3.26
4.78
8.27
7.05
-10.94
-15.79
-14.15
Profit Margin (%)
- -
-3
5
29
18
33
24
8
26
Working Capital
- -
- -
4
2
6
24
22
35
55
LT Debt
- -
- -
15
47
46
68
63
91
135
Total Equity
- -
- -
9.54
6.39
6.97
3.28
- -
- -
- -
Return on Invested Capital (%)
- -
- -
8.76
4.98
7.2
4.63
- -
- -
- -
Return on Capital (%)
- -
- -
10.36
5.1
7.75
5.64
-9.97
-20.77
-16.84
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
17
28
29
LT Borrowings
22
28
27
LT Finance Leases
12
13
27
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
123
129
131
Market Capitalization
524
626
549

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
88
88
80
Cash, Cash Equivalents & STI
33
28
15
Accounts Receivable, Net
22
25
23
Inventories
22
23
28
Total Current Liabilities
80
53
54
Payables & Accruals
- -
- -
- -
ST Debt
17
28
29
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
61.5%
45.27%
Free Cash Flow
- -
321.35%
39.99%
Net Income, GAAP
- -
13.28%
145.78%
Sales/Revenue/Turnover
- -
35.27%
70.33%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
15
15
15
15
59
2025
17
23
29
32
101
2026
32
34
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
- -
-0.09
-0.06
2025
0.01
0.03
0.02
-0.18
-0.13
2026
0.03
-0.01
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
TopGum Industries Ltd. (TASE: TPGM) develops, manufactures, markets and sells dietary and nutraceutical gummy supplements, or gummiceuticals, alongside confectionary gummy candies; core gummiceutical offerings encompass vitamins, minerals, natural extracts, prebiotics, probiotics and functional food products targeting categories such as women's health including fertility, pregnancy, postpartum and menopause support; beauty from within for skin, hair and nails; gut health; immune support; and active lifestyle formulations for energy, endurance, strength and recovery; proprietary technologies feature the patented sugar-free Gummiceuticals Matrix with prebiotic fiber base, TopCaps microencapsulation for flavor masking and targeted delivery, and high-dose platforms enabling elevated active loads without texture compromise; the company also provides private-label, white-label and custom gummy solutions with diverse packaging options including bottles, sachets and pouches; operations span nutritional supplements primarily for international markets and confectionary products including imported sweets mainly for Israel; founded in 2004 by Hai Yakov Hayoun and headquartered at 2 Prague Street in Sderot, Israel, TopGum maintains advanced manufacturing facilities across two continents, employs over 220 professionals including food technologists, pharmaceutical engineers and chemists, and serves global clients through sales teams in the US, Italy, Hong Kong and England; recent developments include the January 2025 acquisition of Island Abbey Nutritionals, a Canadian CDMO specializing in supplement gummies and lozenges, for USD 20 million plus 2025 performance-based earn-out, expected to close in Q1 2025 pending approvals and projecting annual revenue exceeding USD 100 million through expanded North American production, bottling and warehousing capabilities.